Associated Papers
Pharmacogenetic Study of the Dihydropyridine Dehydrogenase Gene in Jordanian Patients with Colorectal Cancer.
Almashagbah NA et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2022
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines.
Lunenburg CATC et al.
European Journal of Human Genetics : Ejhg, 2020
31745289 (PubMed )
Supplement: 41431_2019_540_MOESM1_ESM.docx
Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group.
Bank PCD et al.
Clinical Pharmacology and Therapeutics, 2018
5-fluorouracil toxicity in the treatment of colon cancer associated with the genetic polymorphism 2846 A>G (rs67376798).
González-Perera I et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners, 2017
Pharmacogenetics: from bench to byte--an update of guidelines.
Swen JJ et al.
Clinical Pharmacology and Therapeutics, 2011
Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients.
Savva-Bordalo J et al.
Bmc Cancer, 2010
Should DPD analysis be required prior to prescribing fluoropyrimidines?
Yen JL et al.
European Journal of Cancer (oxford, England : 1990), 2007
Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-Fluorouracil toxicity in Portuguese colorectal cancer patients.
Salgueiro N et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics, 0
Select a paper to view details